Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

cystic fibrosis, Alzheimer’s, Duchnene muscular dystrophy (DMD), and other chronic musculoskeletal disorders. The FDA recently approved CRISPR to treat sickle cell disease, an inherited disorder ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.

Cystic fibrosis (CF) is a life-threatening genetic ... The team developed their CF rabbit model using CRISPR/Cas9 gene-editing technology. Rabbits with CF exhibited hallmark pancreatic changes ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.